Amylin Pharmaceuticals To Present New Data From Broad Diabetes And Obesity Programs At ADA 2007

Main Category: Obesity / Weight Loss / Fitness
Also Included In: Diabetes;  Conferences
Article Date: 20 Jun 2007 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that data featuring its approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline candidates will be presented at the American Diabetes Association's (ADA) 67th Annual Scientific Sessions being held in Chicago, IL from June 22 to 26. The company will also host an investor presentation during the meeting that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and delivery of diabetes care.

Data from several studies will be highlighted in oral presentations and poster sessions that will provide insight into Amylin's approved diabetes drugs, BYETTA and SYMLIN and the company's research and development programs. Additional information will also be presented during two symposia focused on the multihormonal approach to treatment of diabetes and obesity, and the role of incretin-based therapies in type 2 diabetes.

"Our activities at this year's ADA will reinforce the important therapeutic benefits of BYETTA and SYMLIN and focus on novel peptide hormones and their potential to treat obesity," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. "We are dedicated to bringing innovative medicines with life-changing therapeutic potential to patients. Our broad clinical program is designed to continue transforming the care of diabetes and obesity."

KEY AMYLIN ABSTRACTS BEING PRESENTED AT ADA:

1. Oral: "Less Hypoglycemia with Exenatide Versus Insulin Glargine, Despite Similar HbA1c Improvement in Patients with T2DM Adjunctively Treated with Metformin" will be presented by Michael E. Trautmann, M.D. on Sunday, June 24 at 3:45 PM CT (4:45 PM ET).

2. Oral: "Exenatide Maintained Glycemic Control with Associated Weight Reduction Over Three Years in Patients with Type 2 Diabetes" will be presented by John B. Buse, M.D. on Monday, June 25 at 3:15 PM CT (4:15 PM ET).

3. Poster: "Improvements in Cardiovascular Risk Factors Accompanied Improved Glycemic Control and Weight Reduction in Patients with Type 2 Diabetes Treated with Exenatide for 3.5 y" will be presented by David Kendall, M.D. during a poster session on Sunday, June 24 at 12:00 PM CT (1:00 PM ET).

4. Poster: "Pramlintide Improved Glycemic Control without Increased Risk of Hypoglycemia in Patients with Type 2 Diabetes Using Basal Insulin" will be presented by Karen Lutz, Ph.D. during a poster session on Sunday, June 24 at 12:00 PM CT (1:00 PM ET).

5. Oral: "Responsiveness to Leptin Restored by Amylin in Diet Induced Obese (DIO) Rats: Magnitude and Mechanisms of Synergy" will be presented by Jonathan Roth, Ph.D. on Monday, June 25 at 3:45 PM CT (4:45 PM ET).

6. Oral: "Sustained Weight Loss Following 1-y Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity" will be presented by Steven Smith, M.D. on Monday, June 25 at 5:30 PM CT (6:30 PM ET).

A full list of all Amylin abstracts being presented at ADA is available at: http://scientificsessions.diabetes.org.

FEATURED SYMPOSIA

1. "The Diabetes-Obesity Continuum: The Growing Body of Evidence for a Multihormonal Approach to Treatment." This medical education symposium will help healthcare providers understand the potential of multihormonal treatment approaches for diabetes and obesity. The event will be chaired by Carol Hatch Wysham, M.D. on Sunday, June 24 at 5:30 AM CT (6:30 AM ET). This symposium is supported by an unrestricted educational grant from Amylin Pharmaceuticals.

2. "The Role of Incretin-Based Therapies: Reconstructing Treatment Approaches in Type 2 Diabetes." This medical education symposium will help healthcare providers understand the role of incretin-based therapies in relation to type 2 diabetes. The event will be chaired by Bernard Zinman, M.D. on Monday, June 25 at 5:30 AM CT (6:30 AM ET). This symposium is supported by an unrestricted educational grant from Amylin Pharmaceuticals and Eli Lilly and Co.

Amylin will also conduct a webcast for investors to review the information presented at ADA on Sunday, June 24 at 7:30 PM CT (8:30 PM ET). The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately 15 minutes prior to the presentation to register and download any necessary audio software.

More information about ADA can be found at http://scientificsessions.diabetes.org.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. For more information about Amylin visit http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Amylin's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN, and the revenues Amylin generates from these products, may be affected by competition, unexpected new data, technical issues, or manufacturing and supply issues; risks that the results of pre-clinical studies or clinical trials may not be predictive of future results; risks that our clinical trials will not start or be completed when planned; risks that the FDA may not approve Amylin's regulatory submissions; and risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in Amylin's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

Amylin Pharmaceuticals, Inc.
http://www.amylin.com